Drugs for Neglected Diseases initiative - DNDi

dndi.org

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patient-needs driven, not-for-profit research and development (R&D) organization that develops safe, effective, and affordable treatments for the millions of people across the world affected by neglected diseases, notably human African trypanosomiasis (sleeping sickness), leishmaniasis, Chagas disease, filarial infections, paediatric HIV, mycetoma, and hepatitis C.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ASTELLAS, CYTOMX FORM T-CELL ENGAGING CANCER ANTIBODIES PARTNERSHIP

PharmaTimes | March 26, 2020

news image

Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer. The companies have revealed that the deal, which is potentially worth more than $1.6 billion, will focus on several initial programmes, with CytomX leading research and discovery activities, up to clinical candidate selection, which will be funded by Astellas. As part of the deal, Astellas has c...

Read More

PREMIER INC. SUPPORTS FDA, DEA REFORMS AND REGULATORY WAIVERS TO COUNTER DRUG SHORTAGES

Premier Inc. | July 24, 2020

news image

Premier Inc. today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the company believes should be extended beyond the COVID-19 pandemic and made permanent thereafter in order to prevent drug shortages. “During the height of the COVID-19 pandemic, we saw demand for many common pharmaceuticals surge by an average of more than 150 percent,” said Blair Childs, Premier...

Read More

Business Insights, PHARMACY MARKET

TETRIS PHARMA SIGNS SERVICE AGREEMENT WITH SYNEOS HEALTH

Tetris Pharma Ltd | December 13, 2022

news image

Tetris Pharma Ltd a subsidiary of biopharmaceutical company, Arecor Therapeutics plc announces that it has signed a service agreement with Syneos Health® the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, to support the build out of Tetris Pharma’s commercial platform across Europe. Through this partnership, Syneos Health will provide commercial support through an outsourced contract sales services to accelera...

Read More

VIEWS AND ANALYSIS, PHARMACY MARKET

VINCERX PHARMA PRESENTS PRECLINICAL DATA ON VIP943 IN ACUTE MYELOID LEUKEMIA MODELS AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING 2022

Vincerx Pharma, Inc. | December 12, 2022

news image

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022. VIP943 is a novel ADC, which binds to the IL3-receptor alpha chain . VIP943 co...

Read More
news image

ASTELLAS, CYTOMX FORM T-CELL ENGAGING CANCER ANTIBODIES PARTNERSHIP

PharmaTimes | March 26, 2020

Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer. The companies have revealed that the deal, which is potentially worth more than $1.6 billion, will focus on several initial programmes, with CytomX leading research and discovery activities, up to clinical candidate selection, which will be funded by Astellas. As part of the deal, Astellas has c...

Read More
news image

PREMIER INC. SUPPORTS FDA, DEA REFORMS AND REGULATORY WAIVERS TO COUNTER DRUG SHORTAGES

Premier Inc. | July 24, 2020

Premier Inc. today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the company believes should be extended beyond the COVID-19 pandemic and made permanent thereafter in order to prevent drug shortages. “During the height of the COVID-19 pandemic, we saw demand for many common pharmaceuticals surge by an average of more than 150 percent,” said Blair Childs, Premier...

Read More
news image

Business Insights, PHARMACY MARKET

TETRIS PHARMA SIGNS SERVICE AGREEMENT WITH SYNEOS HEALTH

Tetris Pharma Ltd | December 13, 2022

Tetris Pharma Ltd a subsidiary of biopharmaceutical company, Arecor Therapeutics plc announces that it has signed a service agreement with Syneos Health® the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, to support the build out of Tetris Pharma’s commercial platform across Europe. Through this partnership, Syneos Health will provide commercial support through an outsourced contract sales services to accelera...

Read More
news image

VIEWS AND ANALYSIS, PHARMACY MARKET

VINCERX PHARMA PRESENTS PRECLINICAL DATA ON VIP943 IN ACUTE MYELOID LEUKEMIA MODELS AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING 2022

Vincerx Pharma, Inc. | December 12, 2022

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022. VIP943 is a novel ADC, which binds to the IL3-receptor alpha chain . VIP943 co...

Read More